Literature DB >> 2760148

Simultaneous determination of ranitidine and its metabolites in human plasma and urine by high-performance liquid chromatography.

T Prueksaritanont1, N Sittichai, S Prueksaritanont, R Vongsaroj.   

Abstract

A sensitive high-performance liquid chromatographic method was developed for the simultaneous determination of ranitidine and its metabolites, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, in human plasma and urine. For the plasma analysis, 1-ml plasma samples spiked with phenylpyramidol as the internal standard were extracted at basic pH with acetonitrile-ethyl acetate (3:2, v/v). After evaporation and reconstitution, the samples were chromatographed on a cation-exchange column, with a mobile phase of 0.1 M sodium acetate buffer (pH 5)-acetonitrile-tetrahydrofuran (56.5:36:7.5, v/v) and ultraviolet detection at 320 nm. The extraction recoveries were 99.8, 30.4, 74.2 and 80.2% and the detection limits were 5, 15, 10 and 4 ng/ml for ranitidine, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, respectively. For the urine analysis, a simple deproteinization with an equal volume of acetonitrile was satisfactory for sample preparation. The applicability of this method for the pharmacokinetic study of ranitidine following oral administration was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2760148     DOI: 10.1016/s0378-4347(00)82772-3

Source DB:  PubMed          Journal:  J Chromatogr


  2 in total

1.  Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations.

Authors:  Quan Zhou; Zou-Rong Ruan; Hong Yuan; Bo Jiang; Dong-Hang Xu
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

2.  Human jejunal permeability of two polar drugs: cimetidine and ranitidine.

Authors:  N Takamatsu; O N Kim; L S Welage; N M Idkaidek; Y Hayashi; J Barnett; R Yamamoto; E Lipka; H Lennernäs; A Hussain; L Lesko; G L Amidon
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.